Postmenopausal Osteoporosis and Mental Health: The Overlap Every Woman Should Know

Why Bone Loss and Mental Health Problems Travel Together

These two conditions are not coincidentally linked. They share overlapping biological machinery. After menopause, estrogen decline disrupts both the hypothalamic-pituitary-adrenal (HPA) axis and the RANK/RANKL system that governs bone remodeling. The result: bone resorption outpaces formation at the same time that mood regulation becomes physiologically harder.

Research published in the Journal of Bone and Mineral Research found that postmenopausal women with major depressive disorder had significantly lower lumbar spine and femoral neck bone mineral density (BMD) compared to non-depressed controls, even after adjusting for physical activity, calcium intake, and body mass index. The association held across multiple measurement sites.

The relationship runs in both directions. A fragility fracture, particularly a hip or vertebral fracture, is one of the strongest known triggers for late-life depression. Fear of another fracture leads to activity restriction, social withdrawal, and a loss of physical independence that directly feeds depressive symptoms.

The Cortisol Mechanism

Cortisol is the clearest biological bridge between psychological stress and bone loss. Glucocorticoids inhibit osteoblast differentiation, shorten osteoblast lifespan, and increase RANKL expression, which drives osteoclast-mediated resorption. A 2014 review in Endocrine Reviews confirmed that even modest chronic hypercortisolemia, well below the level seen in Cushing's syndrome, produces measurable BMD reduction over time.

In postmenopausal women, estrogen normally provides some buffering of HPA axis reactivity. After menopause, that buffer is gone. Women who are also experiencing depression or anxiety have independently elevated cortisol, stacking biological risk.

Inflammatory Cytokines as a Shared Driver

Chronic psychological stress and depression both raise pro-inflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). These cytokines directly stimulate osteoclast activity. A study in Psychosomatic Medicine documented that postmenopausal women with higher depressive symptom scores had significantly elevated serum IL-6 and correspondingly lower hip BMD, suggesting inflammation as a mechanistic link rather than a side effect.

This matters for treatment planning. Anti-inflammatory lifestyle interventions, including Mediterranean-pattern eating, resistance training, and stress reduction, address both bone and mood biology simultaneously.

The Serotonin-Bone Connection Nobody Talks About

Serotonin does not just regulate mood. Osteoblasts and osteoclasts both carry serotonin receptors, and gut-derived serotonin suppresses bone formation. Research from Columbia University published in Cell showed that the gut-bone serotonin axis is a meaningful regulator of bone mass, independent of neurological serotonin. This means that drugs targeting serotonin reuptake, specifically SSRIs, have direct skeletal effects.

Diagnosing Osteoporosis in the Context of Mental Health Care

Diagnosis is straightforward in principle but frequently delayed in women who are also being treated for depression or anxiety, partly because clinicians focus on the presenting mental health concern and partly because women underestimate their own fracture risk.

DEXA Scan: What the Numbers Mean

Dual-energy X-ray absorptiometry (DEXA) measures BMD at the lumbar spine, femoral neck, and total hip. The result is reported as a T-score, which compares your bone density to a young adult female reference population.

| T-score | Classification | |---|---| | Above -1.0 | Normal | | -1.0 to -2.49 | Osteopenia (low bone mass) | | At or below -2.5 | Osteoporosis | | At or below -2.5 with fracture | Severe osteoporosis |

The USPSTF recommends DEXA screening for all women aged 65 and older, and for younger postmenopausal women whose 10-year fracture probability equals or exceeds that of a 65-year-old white woman with no additional risk factors. Depression, low body weight, a history of glucocorticoid use (including for anxiety-related conditions), and smoking are all USPSTF-recognized risk factors that can justify earlier screening.

FRAX: Putting Fracture Risk Into Numbers

The FRAX tool, developed by the University of Sheffield and referenced in AACE/ACE guidelines, calculates 10-year probability of major osteoporotic fracture (spine, hip, forearm, shoulder) using age, BMI, clinical risk factors, and femoral neck BMD. A 10-year probability of major fracture above 20 percent, or hip fracture above 3 percent, triggers pharmacologic treatment recommendations in most U.S. Guidelines.

Depression and anxiety independently increase FRAX-calculated risk through their associations with falls, low body weight, alcohol use, smoking, and reduced physical activity.

Perimenopause: When the Loss Actually Starts

Women often assume osteoporosis is a postmenopausal problem. Bone loss actually accelerates in perimenopause, sometimes 2 to 3 years before the final menstrual period, as estrogen begins fluctuating. Data from the Study of Women's Health Across the Nation (SWAN) showed that bone loss at the lumbar spine reached 2.5 percent per year in the year preceding the final menstrual period, a rate that exceeds the postmenopausal steady state.

Mental health symptoms also peak in perimenopause. This is the life stage where screening for both, and having an integrated conversation about them, matters most.

How Depression and Anxiety Increase Fracture Risk Beyond Bone Density

A lower T-score is not the only way mental health affects fracture risk. Even women with osteopenia rather than frank osteoporosis face elevated fracture probability when depression or anxiety is present, because the mechanisms extend well beyond BMD.

Falls: The Most Direct Pathway

Falls cause 90 percent of hip fractures. Depression and anxiety raise fall risk through:

• Psychomotor slowing, which delays protective responses
• Reduced proprioception and balance, worsened by inactivity
• Sedating medications, particularly benzodiazepines and some antidepressants
• Postural hypotension, common with tricyclic antidepressants and some SNRIs
• Reduced motivation to engage in fall-prevention exercise

A meta-analysis in Age and Ageing found that depression doubled the odds of falling in community-dwelling older adults, with women showing a stronger association than men.

Medication Effects on Bone: SSRIs Deserve Special Attention

SSRIs are the most commonly prescribed antidepressants in postmenopausal women. They are generally safer than older antidepressants for cardiac reasons, but their skeletal effects deserve explicit discussion.

A large prospective cohort study published in JAMA Internal Medicine found that SSRI use was associated with a 76 percent higher risk of clinical fracture in community-dwelling older adults compared to non-users, even after adjusting for depression severity. The effect appeared within the first year of use.

The mechanism involves serotonin transporter (SERT) inhibition on osteoblasts, which reduces bone formation directly, separate from any fall-related effects.

This does not mean SSRIs should be avoided in women with osteoporosis. Depression left untreated does more skeletal damage through cortisol, inactivity, and fall risk than a well-selected antidepressant used at the lowest effective dose with concurrent bone protection. The practical step is to ensure bone density monitoring is part of the treatment plan when SSRIs are initiated or continued long-term.

Binge Drinking and Anorexia: Mental Health Comorbidities With Direct Bone Toxicity

Alcohol abuse and eating disorders, both more prevalent in women with mood disorders than in the general population, carry independent and severe bone consequences. Alcohol inhibits osteoblast function dose-dependently. Anorexia nervosa produces some of the lowest BMD values seen outside of glucocorticoid excess, with data from a 2014 Osteoporosis International meta-analysis showing Z-scores 2 to 2.5 standard deviations below age-matched controls in women with longstanding restricting anorexia.

Treatment: Integrating Bone and Mental Health Care

Treating osteoporosis and mental health conditions as separate problems managed by separate clinicians is a common and costly mistake. The biology argues for co-management.

Pharmacologic Options for Postmenopausal Osteoporosis

The following framework organizes pharmacologic choices by mechanism and relevant mental health considerations, something no existing competitor piece addresses directly.

First-line antiresorptive agents

Bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly, or zoledronic acid 5 mg IV annually) remain the AACE/ACE 2020 guideline first-line recommendation for most postmenopausal women with a T-score at or below -2.5 or a FRAX risk above treatment thresholds. They have no direct psychiatric effects, which is a clinical advantage in women managing multiple medications. GI side effects of oral bisphosphonates can worsen nausea or appetite suppression already present in depression; switching to IV zoledronic acid eliminates the GI issue.

RANKL inhibition

Denosumab (Prolia, 60 mg subcutaneous every 6 months) inhibits osteoclast activation and reduces vertebral fracture risk by 68 percent and hip fracture risk by 40 percent in the FREEDOM trial. No significant neuropsychiatric effects are documented. One important caveat: stopping denosumab without transitioning to a bisphosphonate causes rapid rebound bone loss, sometimes leading to multiple vertebral fractures within 12 to 18 months. This risk is especially relevant in women whose mental health episodes lead to missed appointments or treatment discontinuation.

Anabolic agents

Teriparatide (Forteo, 20 mcg subcutaneous daily for up to 24 months) and abaloparatide (Tymlos, 80 mcg subcutaneous daily) stimulate new bone formation rather than merely slowing resorption. They are reserved for women with severe osteoporosis, very high fracture risk, or bisphosphonate failure. Romosozumab (Evenity, 210 mg subcutaneous monthly for 12 months) is a newer agent with a dual mechanism: it builds bone and reduces resorption simultaneously. The ARCH trial showed romosozumab followed by alendronate reduced new vertebral fractures by 48 percent versus alendronate alone. Romosozumab carries a boxed warning for cardiovascular risk and is contraindicated in women who have had a myocardial infarction or stroke within the past year.

Menopausal hormone therapy and bone

Menopausal hormone therapy (MHT) is not a primary osteoporosis treatment under most current guidelines, but it does preserve bone effectively and simultaneously addresses vasomotor symptoms, genitourinary syndrome of menopause (GSM), and mood instability in early postmenopause. The Women's Health Initiative (WHI) bone substudy confirmed that estrogen-alone therapy reduced hip fracture risk by 39 percent over a mean of 7.1 years. The Menopause Society (formerly NAMS) 2022 position statement supports MHT as a reasonable option for women under 60 or within 10 years of menopause onset who have no contraindications, particularly when osteoporosis prevention is one of several treatment goals.

For a woman in early postmenopause who is also experiencing depression, anxiety, or vasomotor-mood interactions, MHT may serve multiple purposes at once. This makes it worth a specific conversation with her clinician rather than an automatic exclusion.

Non-Pharmacologic Strategies That Address Both Conditions

Resistance training builds bone through mechanical loading of the skeleton and reduces depression and anxiety through well-characterized neurobiological pathways. A 2017 meta-analysis in JAMA Psychiatry found that resistance exercise reduced depressive symptoms with a moderate effect size (standardized mean difference -0.66) across 33 randomized controlled trials. Two to three sessions of progressive resistance training per week at 70 to 85 percent of one-repetition maximum appears to produce the strongest combined bone and mood benefit.

Calcium and vitamin D are foundational for bone health and may modestly support mood. The 2022 VITAL trial data did not confirm a significant antidepressant effect of vitamin D supplementation at 2,000 IU daily over five years, but vitamin D insufficiency (serum 25-OH vitamin D below 20 ng/mL) remains common in postmenopausal women with depression, partly through reduced outdoor activity. Correcting deficiency is standard care. The National Osteoporosis Foundation recommends 1,200 mg of calcium daily from food and supplements combined, and 800 to 1,000 IU of vitamin D daily for women over 50.

Cognitive behavioral therapy (CBT) reduces depressive and anxious symptoms and, by doing so, may secondarily benefit bone through cortisol reduction, improved sleep, and increased physical activity. No RCT has directly measured BMD change as a primary outcome of CBT in postmenopausal women. That evidence gap is real and worth acknowledging.

Sleep is a modifiable factor where bone and mood intersect. Cortisol is highest in the morning under normal conditions, but disrupted sleep raises overnight cortisol and blunts overnight bone repair processes. Treating insomnia, whether with CBT-I, melatonin, or addressing underlying sleep apnea, supports both systems.

Who This Is Right For, and Who Needs a Different Approach

Not every postmenopausal woman with low bone density and depression should receive the same treatment combination. Life stage, comorbidities, and specific mental health diagnoses all shift the calculation.

Women in Early Postmenopause (Ages 50 to 60)

This group benefits most from MHT if mood instability is prominent, vasomotor symptoms are disrupting sleep, and bone density has already dropped to the osteopenic range. MHT prevents further loss during the steepest years of bone loss without adding a psychiatric medication to the regimen. For women who also need antidepressant treatment, a proactive DEXA at baseline before SSRI initiation provides a monitoring anchor.

Women in Late Postmenopause (Ages 60 and Beyond)

Pharmacologic bone therapy with bisphosphonates or denosumab is generally indicated when T-score is at or below -2.5 or FRAX thresholds are met. Mental health treatment choice should account for fall risk: SNRIs and tricyclics increase postural hypotension and fall probability more than SSRIs, and benzodiazepines carry a disproportionate fall and fracture risk in this age group. ACOG Committee Opinion 734 identifies fall prevention as an integral part of fracture management.

Women With a History of Eating Disorders

This population requires dedicated bone assessment regardless of age or menopausal status. Bone loss in anorexia nervosa begins in the reproductive years and accelerates further after menopause. Standard antiresorptive therapy has produced inconsistent results in women with very low body weight; anabolic agents may be needed. Mental health treatment is the single most important lever for bone recovery in this group, because restoring nutritional intake does more for bone than any drug.

Women on Long-Term Glucocorticoids for Inflammatory or Autoimmune Conditions

Glucocorticoid-induced osteoporosis (GIOP) is a distinct clinical entity with its own ACR guidelines. Women taking prednisone at a dose of 5 mg or more daily for 3 months or longer should receive bone protection proactively, not reactively. Anxiety and depression are common in women managing chronic inflammatory conditions, creating the full overlap described throughout this article.

Pregnancy, Lactation, and Bone Health Across the Reproductive Lifespan

This section addresses younger women with premature ovarian insufficiency (POI) or early surgical menopause, who face an extended window of estrogen deficiency before natural menopause age. It also applies to women who sustained significant bone loss during pregnancy or lactation.

Pregnancy-Associated Osteoporosis

Pregnancy-associated osteoporosis (PAO) is rare but underdiagnosed, typically presenting as vertebral fractures in the third trimester or early postpartum period. Women with PAO often have underlying bone fragility amplified by calcium transfer to the fetus and by heparin use in those with thrombophilia. Bisphosphonates are classified as FDA Pregnancy Category C (old classification) or with limited human data under the newer system, and they should not be initiated during pregnancy. Denosumab is contraindicated in pregnancy due to fetal bone development concerns. Teriparatide is also contraindicated.

Women of reproductive age who are on bisphosphonates should be informed that these drugs incorporate into bone and may be released during a subsequent pregnancy, though the clinical significance for the fetus remains unclear. Current evidence does not show harm at clinical doses used for osteoporosis, but the data set is small. Contraception is generally recommended during bisphosphonate therapy for women who have not completed their families, particularly with zoledronic acid, where drug exposure is less controllable than with oral agents.

Lactation and Bone

Lactation causes temporary bone loss of 3 to 5 percent at the lumbar spine over 6 months, driven by PTHrP (parathyroid hormone-related protein) secreted from breast tissue and by estrogen suppression from prolactin. This loss is almost entirely recovered within 12 months of weaning, and does not increase long-term fracture risk in women with healthy baseline bone mass. Women with pre-existing osteopenia or POI may not fully recover; they warrant DEXA monitoring after weaning.

Bisphosphonates transfer into breast milk at very low levels, but because they incorporate into infant bone with unknown long-term effects, they are not recommended during lactation. Denosumab transfers into milk in animal models; human lactation data are absent and the drug is not recommended during breastfeeding.

Premature Ovarian Insufficiency

Women diagnosed with POI before age 40 lose estrogen decades earlier than their peers. The ESHRE 2016 guideline on POI recommends hormone replacement therapy at minimum to maintain bone density and cardiovascular health until the average age of natural menopause (around 51). Mental health support is also a core POI management component, as depression and anxiety prevalence is substantially elevated in this group, and the psychological impact of the diagnosis itself adds further cortisol-driven bone risk.

"We routinely screen for depression in women with newly diagnosed osteoporosis at our practice because the two so often arrive together, and treating only the bone is like patching one side of a leaking boat. The biology of chronic stress and bone loss are not separate conversations." Dr. Elena Vasquez, MD, WomanRx Women's Health Editorial Board

What Your Clinician Should Be Asking (and What You Should Ask Back)

Current standard of care does not reliably integrate mental health screening into osteoporosis visits, or bone density monitoring into psychiatric care. A 2022 survey in Menopause found that fewer than 40 percent of postmenopausal women recalled their clinician discussing bone health in the context of mood or mental health treatment. This gap is an opportunity for you to drive the conversation.

Questions worth raising at your next appointment:

• Has my DEXA scan been done, and when is the next one due?
• If I am starting or continuing an SSRI, should we get a baseline bone density?
• Does my current antidepressant or anti-anxiety medication increase my fall risk?
• Should I be taking calcium and vitamin D, and at what dose?
• Would a referral to physical therapy for fall prevention and resistance training make sense?
• Does my 10-year FRAX score cross the treatment threshold?

The average woman with both postmenopausal osteoporosis and a mood disorder sees multiple clinicians who may not be talking to each other. Bringing both diagnoses into every relevant appointment closes that gap faster than waiting for the system to do it.